[7]
The notion that a second person could allege that its drug will not infringe a claim by reference to a given patent, without first having ascertained the scope and extent of the patent in issue, is on the face of it unacceptable and likely to give rise to vexatious proceedings. Granted, this is new law, but it is not so complicated as to justify a complete disregard for its obvious premises. Clearly, the
Regulations
never envisaged the issuance of pro forma of allegation. Regulation 5(3) makes it clear that it can only be issued once the factual and legal basis for the allegation have been ascertained.